Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;8(3):e703-e708.
doi: 10.7861/fhj.2021-0063.

Patient and public understanding of the concept of 'personalised medicine' in relation to cancer treatment: a systematic review

Jed Botham  1 , Valerie Shilling  2 , John Jones  1
Affiliations
Review

Patient and public understanding of the concept of 'personalised medicine' in relation to cancer treatment: a systematic review

Jed Botham et al. Future Healthc J. 2021 Nov.

Abstract

Personalised medicine (PM) is becoming increasingly integrated into standard clinical practice for treating numerous diseases, including cancer. Implementing PM into healthcare systems will only be successful with the acceptance and input of both patients' and public opinion. This review, therefore, aimed to identify both patients' and public understanding, and perceived benefits and concerns of PM in cancer treatment. A literature search was conducted using MEDLINE, EMBASE, PsycINFO and CINAHL databases. The eligibility criteria specified that papers must explore the public or patients' understanding of PM or pharmacogenomic (PGx) testing in relation to cancer treatment. Patients have a greater understanding of, and trust in, PM compared with members of the public, but often misunderstand how genomic testing in PM works. Key areas that can be targeted to inform future health literacy interventions include genetic literacy for the public and understanding of how PM testing and treatment works for patients.

Keywords: cancer; genomics; patients’ understanding; personalised medicine; public understanding.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Identification and selection of eligible studies.
See this image and copyright information in PMC

References

    1. Department of Health and Social Care, Department for Business, Energy & Industrial Strategy, Office for Life Sciences, Lord Bethell of Romford . Genome UK: the future of healthcare. GOV.UK, 2020. [Accessed 29 October 2020]. www.gov.uk/government/publications/genome-uk-the-future-of-healthcare
    1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in the UK until 2035. Br J Cancer 2016;115:1147–55. - PMC - PubMed
    1. Holden C, Bignell L, Mukhopadhyay S, Jones C. The public perception of the facilitators and barriers to implementing personalized medicine: A systematic review. Per Med 2019;16:409–20. - PubMed
    1. Day S, Coombes RC, McGrath-Lone L, Schoenborn C, Ward H. Stratified, precision or personalised medicine? Cancer services in the ‘real world’ of a London hospital. Sociol Health Illn 2017;39:143–58. - PubMed
    1. Lerman C. BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA 1996;275:1885. - PubMed